Category: Press Releases

(Collingwood, Ont., May 21, 2021) – deutraMed Inc., a breakthrough deuterium science and innovation company, today congratulated Grade 8 student Tyson Neufeld for winning the deutraMed-sponsored Chemistry and Innovation Award at the Canada-Wide Science Fair (CWSF).

Neufeld, a student at Mountain Christian School in Dawson Creek, BC, won the award in the science fair’s Grade 7 and 8 Junior Category. His project, “Microbial Fuel Cells for Improved Contaminated Soil Clean up and BioElectricity Generation”, also won the Junior Category “Energy Challenge” and separately, an award at the recent Northern BC Regional Science Fair.

“Tyson impressed me and other judging team members with his innovative thinking and excellent presentation,” said Sofia Kalil, Team Leader – Electrochemistry & Intellectual Property at deutraMed. “Congratulations on your achievement, Tyson!”

The Canada-Wide Science Fair, held virtually May 17-21, 2021, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects from across the country. The Chemistry and Innovation Award recognizes the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry.

deutraMed, which produces value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors, sponsored the award as part of its commitment to fostering Canada’s next generation of STEM innovators and entrepreneurs.

The CWSF annually brings together Canada’s top STEM talent at the middle and high school levels. According to the Science Fair’s organizer, Youth Science Canada, every year more than 500,000 young Canadians participate in project-based science, about the same number who are involved in minor hockey.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com

Collaboration seeks to alleviate cold storage requirements for mRNA COVID vaccines, enhance other medical therapeutics

(Sherbrooke, Que. and Collingwood, Ont., May 21, 2021) – Université de Sherbrooke and KEY DH Technologies Inc. subsidiary deutraMed Inc. today announced a collaboration to accelerate the development of deutraMed’s innovative Biomolecule Stabilization Technology platform.

The $500,000 project seeks to further validate the platform’s effectiveness in stabilizing mRNA COVID vaccines and a wide range of other advanced medical therapeutics. It is supported jointly with cash and in-kind contributions from deutraMed, Universite de Sherbrooke and MITACS, a national, not-for-profit organization that works with universities, businesses, federal, and provincial governments to deliver research and training programs. 

The successful advancement of deutraMed’s stabilization platform could enable mRNA COVID vaccines to be stored and transported at higher temperatures than is possible now. This would resolve significant logistical challenges to global vaccine distribution caused by the need for storage at temperatures as low as -70 degrees Celsius.

“Université de Sherbrooke is playing a key role in our efforts to accelerate deutraMed’s Biomolecule Stabilization Technology platform,” says Andrew Stuart, President and CEO, KEY DH Technologies. “The university has the laboratory facilities and people required to do this, notably Professor Denis Gris, a well-known and respected research scientist in the fields of cellular and molecular immunology.” 

deutraMed’s stabilization platform utilizes the company’s BioPure Deuterium Oxide™ product. The platform stabilizes certain active pharmaceutical ingredients, thereby enabling medical treatments which would otherwise not be practical due to the inherent instability of the advanced medicines themselves.

mRNA is the foundation of many new advanced therapeutics where stabilization can offer significant potential benefits. These include treatments currently in development and undergoing clinical trials for diabetes, cancer, cardiovascular diseases, infectious diseases and other medical conditions.

“I am delighted to collaborate with deutraMed in its cutting-edge work on mRNA stabilization, with support from the MITACS program,” said Professor Gris, Université de Sherbrooke, Département de Pharmacologie et Physiologie. “This work will help advance an important emerging field of therapeutics.”

About KEY DH Technologies Inc.

KEY DH Technologies develops innovation-driven businesses in the deuterium and hydrogen industries, serving global markets. KEY’s three main operating companies include: Hydrogen Optimized, a private hydrogen technology company that develops and commercializes the patent-pending RuggedCell™ water electrolysis systems for the large-scale production of Green Hydrogen; Isowater®, a world-leading supplier of deuterium oxide to global customers in the life sciences, high technology and environmental science sectors; and deutraMed™, a breakthrough deuterium science and innovation company that provides clients with high-value deuterium-containing products for specialized applications along with IP-driven research and services. For more information, please visit https://keydht.com.

About deutraMed Inc.

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com. 

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com

Company aims to encourage interest and achievement in STEM studies among young Canadians

(Collingwood, Ont., May 11, 2021) – deutraMed Inc., a breakthrough deuterium science and innovation company, today proudly announced its support for the Canada-Wide Science Fair (CWSF). The Science Fair, to be held virtually May 17-21, 2021, is Canada’s foremost annual youth science, technology, engineering and mathematics (STEM) event, bringing together top young scientists and their projects from across the country.

deutraMed, which produces value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors, is sponsoring CWSF’s Chemistry and Innovation Award for Grade 7 and 8 students. The award, to be announced on May 20, will recognize the Grade 7 or 8 student whose project demonstrates outstanding innovation in chemistry. 

“deutraMed’s support for the Canada-Wide Science Fair reflects our commitment to fostering Canada’s next generation of STEM innovators and entrepreneurs,” says Lisa Stuart, Managing Director, deutraMed. “Our goal in sponsoring the Chemistry and Innovation Award is to recognize promising young STEM students for their ingenuity, determination and hard work, and to encourage them to continue on the path to becoming Canada’s future STEM leaders.” 

The winner of the Grade 7/8 CWSF Chemistry and Innovation Award will be selected by Sofia Kalil, Team Leader – Electrochemistry & Intellectual Property at deutraMed. Ms. Kalil is a Chemical Engineering student at the University of Toronto.

“As an organization based on scientific innovation, we depend on the creative talent and technical contributions of recent STEM graduates and coop students for our success,” Ms. Kalil says. “In just a few years, today’s young science fair participants will be central to the success not only of companies like ours, but also Canada’s economy.”

The CWSF annually brings together Canada’s top STEM talent at the middle and high school levels. According to the Science Fair’s organizer, Youth Science Canada, every year more than 500,000 young Canadians participate in project-based science, about the same number who are involved in minor hockey.

About deutraMed Inc. 

deutraMed™ is a breakthrough deuterium science and innovation company. We meet the growing demand for value-added deuterium-containing ingredients used mainly in the Life Sciences and High Technology sectors. We also provide research and services for next-generation deuterium products in partnership with our clients, and conduct IP-driven R&D for biopharma and bio-materials applications with support from a world-class Scientific Advisory Board. DeutraMed is a member of the KEY DH Technologies Inc. group of companies. For more information, please visit www.deutraMed.com.  

For more information:

Don Hogarth
Phone: 416-565-8920
Email: don@hogarthpr.com 

DEUTRAMED^™ INC. ANNOUNCED PROGRESS WITH mRNA VACCINE COLD CHAIN STABILIZATION TECHNOLOGY

Collingwood, ON, Canada – November 17^th, 2020 – deutraMed^™ Inc. is pleased to announce significant progress with its Biomolecule Stabilization Technology platform.  Results from recent testing provides evidence that stabilization of mRNA was achieved.  mRNA is the foundation of many new advanced therapeutics including the recently announced COVID-19 vaccines by both Moderna and pharmaceutical giant Pfizer Inc.

“The cold chain supply challenge for complex therapeutics, including vaccines, is a significant hurdle for their delivery to the global population.” Said Lisa Anne Stuart, Managing Director of deutraMed™ Inc.  “Our Biomolecule Stabilization Technology platform addresses this issue.  History has examples, such as the polio vaccine, where failed cold chain supply would inactivate the vaccine.  The rapidly growing number of mRNA-based therapeutics in the pharmaceutical industry pipeline requires solutions for successful logistics of distribution in the future.  For example, for the recently announced Pfizer mRNA-based COVID-19 vaccine, it is thought that immunization will require two doses delivered from a vaccine supply, stored and shipped at temperatures less than 70°C below zero.  The infrastructure requirements (including road, aircraft, trucking and intermodal handling) to ensure effective cold chain supply are not established for such stringent conditions. deutraMed is advancing solutions for this infrastructure which could lower cost and improve molecule distribution success as well as make it easier for people to receive effective medication.”

“The advance being announced today provides evidence of our progress to stabilize mRNA.” noted Dr. Joseph P. Porwoll, Chairman of deutraMed Inc.  “Stabilized mRNA provides foundational support for preserving bio-molecules used in medicine. I am proud of our leading deuterium experts in our Scientific Advisory Board who identified multiple deuterium technology pathways and recommended Biomolecule Stabilization as a top priority in 2019.  Clearly the impact of COVID-19 on the world has heightened the urgency of our technology and our scientists are starting to create results.”

On March 5^th 2020, deutraMed^™ announced the introduction of its BioPure Deuterium Oxide™ products.  This non-compendial excipient stabilizes certain active pharmaceutical ingredients (APIs).  BioPure Deuterium Oxide™ enables medical treatments which would otherwise not be practical due to the inherent instability of the advanced medicines themselves.

Deuterium use in the pharmaceutical and the life sciences industry is expanding.  Replacing protium, the most abundant isotope of hydrogen, with deuterium has enabled life science innovators to harness the deuterium isotope to their advantage.  The bond strength between deuterium and carbon is greater than protium and carbon, thus replacing light hydrogen with deuterium modifies some of the physical, chemical and biochemical properties of non-deuterated compounds. Published investigations and patents illustrate the wide range of life science possibilities for deuterated ingredients administered through skin, intermuscular, intravenous, oral, and ocular pathways.

About deutraMed^™ Inc.

deutraMed™ Inc. was formed in 2017 to meet the expanding global demand for deuterium containing ingredients and deuterium expertise. Founded by a group of industry specialists, the deutraMed™ team identified the need for expertise in deuterium science and innovation to achieve a focused and reliable supply of deuterium ingredients including deuterium gas, deuterium compounds, and intellectual property driven research and services. With applications in the life sciences to high technology, deuterium ingredients are being used globally to create a healthy and connected world. It is our duty to deliver innovations in deuterium ingredients to our clients.

deutraMed™ Inc. works with customers individually, using secure deuterium supply, expertise, and premium CMO/CRO/CDMO services to advance custom deuterium innovations in parallel with strategic growth milestones.

For more information please contact:

Media Relations

Darren MacVicar
deutraMed Inc.

Email: darren.macvicar@deutramed.com
Phone: (833) 338 8726 ext 705                                                                            
40 Sandford Fleming Drive Collingwood ON, Canada L9Y 4V7

Substituting deuterium for protium at carbon-hydrogen chemical bond locations targeted by metabolic enzymes can help to slow down the breakdown of a drug, thus increasing its half-life in the body. This is due to the kinetic isotope effect, which increases the bond strength between deuterium and carbon in comparison to protium-carbon bond. Longer duration of action of a drug means that patients can take their medication less frequently without decreasing the efficacy of treatment. As additional benefits to the patient, deuteration can reduce drug interactions due to metabolic switching, and increase the patient’s tolerance of a medication.

What are deuterated drugs?

The first deuterated drug to enter the market was deutetrabenazine (deuterated tetrabenazine) from Teva pharmaceuticals in 2017, and it is intended for the treatment of Huntington’s chorea. The benefits of deuteration for this drug are the extended half-life and more stable blood levels of an active metabolite.

Another example of the attractiveness of deuterated pharmaceuticals is the deuterium chemistry platform for drug discovery at Concert Pharmaceuticals, based in Lexington, KY. Their current pipeline includes CTP-543 (deuterated ruxolitinib) in Phase III clinical trials for the treatment of Alopecia areata, and CTP-692 (a deuterium-modified form of D-serine) in Phase II clinical trials for the treatment of schizophrenia.

It has also been shown, that deuteration can help to stabilize drug enantiomers. Although there has been limited exploration in this area outside of basic scientific experiments, this approach could prove to be extremely beneficial in harnessing the potential of pure enantiomers over racemic mixtures. For example, deuteration of the chiral center was explored in stabilizing the enantiomers of thalidomide, because they have unique pharmacological profiles.

Deuteration has the potential to solve several issues with many current drugs, and it is a feasible tool that medicinal chemists should keep in their toolbox.  We at deutraMed will be following closely the momentum that deuterated pharmaceuticals are gaining.

About deutraMed

Where do we fit into this story? deutraMed was created in 2017 to help supply deuterated ingredients. The founders, a diverse team of industry professionals, saw a need for a focused and reliable supply of such ingredients. And, it’s not just the drug industry that can benefit from deuterated ingredients. These compounds have applications in a number of fields, from the life sciences to high technology.

Our experts can help you with leading deuterium solutions, expertise, long-term supply, CRO and CMO partnerships, and new product releases. Schedule a call with our experts to learn more.

To find out more about our company, gasworld took the time to talk to Robert Clark, Vice-President of deutraMed, about our deuterium gas (Heavy Hydrogen) product offerings and what we have been working on so far this year.

“After refining our operations to provide deuterium gas for the global fibre optic market, we are now focusing on creating custom, higher-grade products which cater to research and semiconductor industries” – Robert Clark, Vice President

Read the article here

Learn more about our deuterium gas here

To all our valued customers and partners:

This has been a challenging time around the world and in Canada.  Knowing that you might have concerns we want to reassure that the safety, security and best interest of our customers, partners, employees and operations are at the core of what we do. 

We want to assure you that we are taking all appropriate measures and precautions to ensure our production and supply lines are operational, safe and secure and that we have existing plans and protocols in place to ensure that they stay that way.

We at deutraMed are acutely aware of the situation and are working hard to mitigate the impacts of any disruption using our robust business continuity plan.

We are working hard to continue to provide the best service and secure supply. We are in contact with our suppliers and customer to ensure we can respond quickly to any changes in the situation.  We all have to work together at this time to ensure the stability of supply lines and to ensure that the finished products continue to be available to the ultimate customer.

Please reach out to us to discuss your needs so we can properly plan for and support your mitigation strategies.

If you have any further questions on the subject, please contact deutraMed Inc. at +1(833)338-8726 or info@deutramed.com.